Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Dermatology > PsoBarrier EU: Large survey evaluating quality of care in Europe

PsoBarrier EU: Large survey evaluating quality of care in Europe

Presented by
Dr Anna Langenbruch, Universitätsklinikum Hamburg-Eppendorf, Germany
Conference
WPPAC 2021
Trial
PsoBarrier EU
    The PsoBarrier EU study was a European effort investigating over 1,300 patients with psoriasis. This study was awarded the best educational poster for furthering our understanding of how psoriasis and possibly psoriatic arthritis can be effectively treated with available measures [1]. This is one of the first international studies on barriers in psoriasis care.

    A previous nationwide study demonstrated that psoriasis care continuously improved in Germany between 2004 and 2017, although some deficits persist. Few comparable studies in European countries were available. The PsoBarrier EU analysed the quality of healthcare in 4 European countries: Spain, Germany, Denmark, and Poland [2,3]. Patients were asked identical questions on a broad spectrum of issues, mainly patient-reported outcomes, but also questions about the severity of the disease.

    Dr Anna Langenbruch (Universitätsklinikum Hamburg-Eppendorf, Germany) shared the results of the study concerning the long-term perspective of psoriasis and the therapeutic course in time [1]. Severity measured by PASI and quality of life measured by DLQI were highest in patients from Poland compared with the other countries, suggesting differences in healthcare between the participating countries. Nonetheless, satisfaction with the treatment was similar in Poland (65.1%) compared with Spain (68.5%), albeit lower than in Denmark (86.7%) and Spain (90.9%).

    The next step will be to further analyse predictors of barriers for guideline-compliant treatment and to interpret those in the light of the respective healthcare system, and to identify needs for further action, which can be different depending on the healthcare system.

    1. Langenbruch A. Quality of care and barriers to care for psoriasis in Europe – results of the PsoBarrier EU study. Poster P76, 6thWorld Psoriasis & Psoriatic Arthritis Conference, 30 June–3 July 2021.
    2. Augustin M, et al. Arch Dermatol Res. 2016;308:389–400.
    3. Langenbruch A, et al. J Eur Acad Dermatol Venereol. 2021;35:1536–42.

     

    Copyright ©2021 Medicom Medical Publishers



    Posted on